Find the latest oncology news for your sub-specialty area
A University of Colorado Cancer Center study presented at the American Society for Clinical Oncology…
Crizotinib and entrectinib are both active against ROS1 non-small cell lung cancer. But which is…
Igor Puzanov, MD, Director of the Early Phase Clinical Trials Program and Chief of Melanoma…
Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response…
A precision medicine targeting a key protein which helps cancer cells to tolerate DNA damage…
The KEYNOTE-062 phase III randomised clinical trial achieved its primary endpoint, showing that for patients…
The international, randomised phase III MONALEESA-7 trial found that adding ribociclib to standard-of-care endocrine therapy…
Five-year data from the phase Ib KEYNOTE-001 clinical trial show that pembrolizumab was safe and…
Crizotinib was the first drug licensed to treat ALK-positive non-small cell lung cancer (ALK NSCLC).…
A study of samples from patients with multiple myeloma (MM) has demonstrated how “reprogrammed” fat…